Investors

Data Presentations

Data Presentations

Congress Date	Title	Authors
Presented at ASN Kidney Week 2021	Comprehensive Safety Profile of Vadadustat from Global Phase 3 Clinical Trials	R. Agarwal, D. Vargo, W. Luo, B. Maroni, C. Solinsky, G. Chertow
Presented at ASN Kidney Week 2021	Vadadustat for Treatment of Anemia in Patients with Dialysis-Dependent CKD Receiving Peritoneal Dialysis	G. Chertow, N. Boudville, P. Chowdhury, C. Gonzalez, L. Kooienga, W. Luo, B. Maroni, K. Ntoso, D. Vargo, K. Eckard
Presented at ASN Kidney Week 2021	Vadadustat, an Oral HIF-PHI, Is Not Associated with Increased Risk of Neoplasm in Patients with Anemia Due to CKD	R. Agarwal, D. Vargo, W. Luo, B. Maroni, C. Solinsky, G. Chertow
Presented at ASN Kidney Week 2021	Thromboembolic Events with Vadadustat vs Darbepoetin Alfa for Anemia Treatment in Patients with Dialysis-Dependent CKD	P. Parfrey, W. Luo, B. Maroni, R. Anders, D. Vargo, P. McCullough
Presented at ASN Kidney Week 2021	Assessment of Thromboembolic Events with Vadadustat vs Darbepoetin Alfa for Treatment of Anemia in Patients with Non–Dialysis-Dependent CKD	P. McCullough, W. Luo, B. Maroni, R. Anders, D. Vargo, P. Parfrey
Published in NDT on November 16, 2020	Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials	K. Eckardt, R. Agarwal, Y.Farag, A. Jardine, Z. Khawaja, M. Koury, W. Luo, K. Matsushita, P. McCullough, P. Parfrey, G. Ross, M. Sarnak, D. Vargo, W. Winkelmayer, G. Chertow
Presented at NKF Spring Clinical Meetings 2020	The Effect of Food Intake on the Pharmacokinetics of Vadadustat Following Single Dose Administration	R. Sawant, S. Paulson, L. Burke, P. Navarro, B. Schwartz and A. Chavan
Presented at NKF Spring Clinical Meetings 2020	Evaluation of Drug Interaction with Multiple Doses of Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of Vadadustat	R. Sawant, S. Paulson, L. Burke, S. Sani, B. Schwartz and A. Chavan
Presented at NKF Spring Clinical Meetings 2020	Impact of Vadadustat on Iron Regulation in Japanese Subjects with Chronic Kidney Disease (CKD)	C. Solinsky, Y. Farag, Z. Khawaja, R. Anders, W. Luo, A. Chavan, D. Vargo, G. Ross, R. Agarwal, M. Nangaku
Presented at ASN Kidney Week 2019	Randomized, Double-Blinded, Active-Controlled (Darbepoetin Alfa), Phase 3 Study of Vadadustat in Chronic Kidney Disease Patients With Anemia on Hemodialysis in Japan	M. Nangaku, K. Kondo, K. Ueta, Y. Kokado, G. Kaneko, H. Matsuda, Y. Kawaguchi, Y. Komatsu

Print Page

Email Page

Contact IR

Email Alerts

Tear Sheet

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098 phone
+1 617.871.2099 fax